Sialic acid catabolism by N-acetylneuraminate pyruvate lyase is essential for muscle function. JCI insight Wen XY and Tarailo-Graovac M and Brand-Arzamendi K and Willems A and Rakic B and Huijben K and Da Silva A and Pan X and El-Rass S and Ng R and Selby K and Philip AM and Yun J and Ye XC and Lefeber DJ DOI: 10.1172/jci.insight.122373 PubMed: 30568043 12/2018
Gene Expression Profiling of Endoplasmic Reticulum Stress in Hepatitis C Virus-Containing Cells Treated with an Inhibitor of Protein Disulfide Isomerases. ACS omega Özcelik D and Seto A and Rakic B and Farzam A and Supek F and Pezacki JP DOI: 10.1021/acsomega.8b02676 PubMed: 30775641 12/2018
Benzofuran-derived cyclic beta-amino acid scaffold for building a diverse set of flavonoid-like probes and the discovery of a cell motility inhibitor. Organic letters DOI: 10.1021/ol800050g PubMed: 18302395 03/2008
Synthesis of (2)-Cytoxazone and (1)-epi-Cytoxazone: the chiral pool approach Synthetic Communications 2005
Rare Diseases: Models and Mechanisms Network: N-Acetylneuraminate pyruvate lyase (NPL) deficiency Functional validation in mouse, $20,000. Conivestigators: Dr. Clara van Karnebeek and Dr. Alexey Pshezhetsky
Rare Disease Foundation and BC Children’s Hospital Foundation (BCCHF): GBA2 validation, $3500. Coinvestigator: Dr. Gabriella Horvath
Honours & Awards
2009-2012 - NSERC Postdoctoral Fellowship
2005 - Pfizer Award for Outstanding Achievement, Bio-Organic Gordon Research Conference
2014 - Linda Stevens Memorial Fund Garrod Conference Travel Award 2014
Human DNA testing could improve outcomes for patients with COVID-19.
That’s the key idea put forth in preliminary research posted this month to bioRxiv that highlights the potential benefits of testing COVID-19 patients for genetic variants of ACE2—the protein identified as the point-of-entry for the SARS-COV-2 virus into human cells.
Congratulations to the BC Children's and BC Women's investigators who were awarded funding through the highly competitive Canadian Institutes of Health Research (CIHR) Project Grant Fall 2019 competition.
A new study suggests that specialized immune cells that dampen inflammation and help repair the gut could be used as a potential therapy for children dealing with the painful symptoms of inflammatory bowel disease.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.